PMID- 34526770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 17
DP  - 2021
TI  - Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and 
      Radical Cure: Overview and Perspectives.
PG  - 989-999
LID - 10.2147/TCRM.S269336 [doi]
AB  - This article is inter alia a brief, first-stop guide to possible adverse events 
      (AEs) associated with tafenoquine (TQ) intake. Safety and efficacy findings for 
      TQ in Plasmodium vivax malaria prophylaxis and radical cure are summarized and 
      some of the latest TQ-related studies (published in 2020 and 2021) are 
      highlighted. In addition, little-known biological and other matters concerning 
      malaria parasites and 8-aminoquinoline (8-AQ) drug action are discussed and some 
      correct terminology pertinent to malaria is explained.
CI  - (c) 2021 Markus.
FAU - Markus, Miles B
AU  - Markus MB
AUID- ORCID: 0000-0002-3843-8409
AD  - School of Animal, Plant and Environmental Sciences, Faculty of Science, 
      University of the Witwatersrand, Johannesburg, South Africa.
AD  - Wits Research Institute for Malaria, School of Pathology, Faculty of Health 
      Sciences, University of the Witwatersrand, Johannesburg, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20210908
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC8435617
OTO - NOTNLM
OT  - G6PD
OT  - WR238605
OT  - chloroquine
OT  - hypnozoite
OT  - primaquine
OT  - relapse
COIS- The author declares that he has no conflicts of interest, financial or otherwise.
EDAT- 2021/09/17 06:00
MHDA- 2021/09/17 06:01
PMCR- 2021/09/08
CRDT- 2021/09/16 07:03
PHST- 2021/04/26 00:00 [received]
PHST- 2021/08/20 00:00 [accepted]
PHST- 2021/09/16 07:03 [entrez]
PHST- 2021/09/17 06:00 [pubmed]
PHST- 2021/09/17 06:01 [medline]
PHST- 2021/09/08 00:00 [pmc-release]
AID - 269336 [pii]
AID - 10.2147/TCRM.S269336 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2021 Sep 8;17:989-999. doi: 10.2147/TCRM.S269336. 
      eCollection 2021.